Generation of a single-cycle replicable Rift Valley fever vaccine

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) is an arbovirus that causes severe disease in humans and livestock in sub-Saharan African countries. The virus carries a tripartite, single-stranded, and negative–sense RNA genome, designated as L, M, and S RNAs. RVFV spread can be prevented by the effective vaccination of animals and humans. Although the MP-12 strain of RVFV is a live attenuated vaccine candidate, MP-12 showed neuroinvasiveness and neurovirulence in young mice and immunodeficiency mice. Hence, there is a concern for the use of MP-12 to certain individuals, especially those that are immunocompromised. To improve MP-12 safety, we have generated a single-cycle, replicable MP-12 (scMP-12), which carries L RNA, S RNA encoding green fluorescent protein in place of a viral nonstructural protein NSs, and an M RNA encoding a mutant envelope protein lacking an endoplasmic reticulum retrieval signal and defective for membrane fusion function. The scMP-12 undergoes efficient amplification in the Vero-G cell line, which is a Vero cell line stably expressing viral envelope proteins, while it undergoes single-cycle replication in naïve cells and completely lacks neurovirulence in suckling mice after intracranial inoculation. A single-dose vaccination of mice with scMP-12 confers protective immunity. Thus, scMP-12 represents a new, promising RVF vaccine candidate. Here we describe protocols for scMP-12 generation by using a reverse genetics system, establishment of Vero-G cells, and titration of scMP-12 in Vero-G cells.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages187-206
Number of pages20
Volume1403
DOIs
StatePublished - Apr 1 2016

Publication series

NameMethods in Molecular Biology
Volume1403
ISSN (Print)10643745

Fingerprint

Rift Valley Fever
Vero Cells
Rift Valley fever virus
Vaccines
Gastrin-Secreting Cells
RNA
Vaccination
Phlebovirus
Viral Nonstructural Proteins
Bunyaviridae
Viral Envelope Proteins
Arboviruses
Reverse Genetics
Cell Line
Attenuated Vaccines
Membrane Fusion
Livestock
Mutant Proteins
Green Fluorescent Proteins
Endoplasmic Reticulum

Keywords

  • Reverse genetics
  • Rift Valley fever virus
  • Single-cycle replicable virus
  • Stable cell establishment
  • Transfection
  • Vaccine

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Murakami, S., Terasaki, K., & Makino, S. (2016). Generation of a single-cycle replicable Rift Valley fever vaccine. In Methods in Molecular Biology (Vol. 1403, pp. 187-206). (Methods in Molecular Biology; Vol. 1403). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3387-7_9

Generation of a single-cycle replicable Rift Valley fever vaccine. / Murakami, Shin; Terasaki, Kaori; Makino, Shinji.

Methods in Molecular Biology. Vol. 1403 Humana Press Inc., 2016. p. 187-206 (Methods in Molecular Biology; Vol. 1403).

Research output: Chapter in Book/Report/Conference proceedingChapter

Murakami, S, Terasaki, K & Makino, S 2016, Generation of a single-cycle replicable Rift Valley fever vaccine. in Methods in Molecular Biology. vol. 1403, Methods in Molecular Biology, vol. 1403, Humana Press Inc., pp. 187-206. https://doi.org/10.1007/978-1-4939-3387-7_9
Murakami S, Terasaki K, Makino S. Generation of a single-cycle replicable Rift Valley fever vaccine. In Methods in Molecular Biology. Vol. 1403. Humana Press Inc. 2016. p. 187-206. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3387-7_9
Murakami, Shin ; Terasaki, Kaori ; Makino, Shinji. / Generation of a single-cycle replicable Rift Valley fever vaccine. Methods in Molecular Biology. Vol. 1403 Humana Press Inc., 2016. pp. 187-206 (Methods in Molecular Biology).
@inbook{0c0d868890a040628071829415c15840,
title = "Generation of a single-cycle replicable Rift Valley fever vaccine",
abstract = "Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) is an arbovirus that causes severe disease in humans and livestock in sub-Saharan African countries. The virus carries a tripartite, single-stranded, and negative–sense RNA genome, designated as L, M, and S RNAs. RVFV spread can be prevented by the effective vaccination of animals and humans. Although the MP-12 strain of RVFV is a live attenuated vaccine candidate, MP-12 showed neuroinvasiveness and neurovirulence in young mice and immunodeficiency mice. Hence, there is a concern for the use of MP-12 to certain individuals, especially those that are immunocompromised. To improve MP-12 safety, we have generated a single-cycle, replicable MP-12 (scMP-12), which carries L RNA, S RNA encoding green fluorescent protein in place of a viral nonstructural protein NSs, and an M RNA encoding a mutant envelope protein lacking an endoplasmic reticulum retrieval signal and defective for membrane fusion function. The scMP-12 undergoes efficient amplification in the Vero-G cell line, which is a Vero cell line stably expressing viral envelope proteins, while it undergoes single-cycle replication in na{\"i}ve cells and completely lacks neurovirulence in suckling mice after intracranial inoculation. A single-dose vaccination of mice with scMP-12 confers protective immunity. Thus, scMP-12 represents a new, promising RVF vaccine candidate. Here we describe protocols for scMP-12 generation by using a reverse genetics system, establishment of Vero-G cells, and titration of scMP-12 in Vero-G cells.",
keywords = "Reverse genetics, Rift Valley fever virus, Single-cycle replicable virus, Stable cell establishment, Transfection, Vaccine",
author = "Shin Murakami and Kaori Terasaki and Shinji Makino",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/978-1-4939-3387-7_9",
language = "English (US)",
volume = "1403",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "187--206",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Generation of a single-cycle replicable Rift Valley fever vaccine

AU - Murakami, Shin

AU - Terasaki, Kaori

AU - Makino, Shinji

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) is an arbovirus that causes severe disease in humans and livestock in sub-Saharan African countries. The virus carries a tripartite, single-stranded, and negative–sense RNA genome, designated as L, M, and S RNAs. RVFV spread can be prevented by the effective vaccination of animals and humans. Although the MP-12 strain of RVFV is a live attenuated vaccine candidate, MP-12 showed neuroinvasiveness and neurovirulence in young mice and immunodeficiency mice. Hence, there is a concern for the use of MP-12 to certain individuals, especially those that are immunocompromised. To improve MP-12 safety, we have generated a single-cycle, replicable MP-12 (scMP-12), which carries L RNA, S RNA encoding green fluorescent protein in place of a viral nonstructural protein NSs, and an M RNA encoding a mutant envelope protein lacking an endoplasmic reticulum retrieval signal and defective for membrane fusion function. The scMP-12 undergoes efficient amplification in the Vero-G cell line, which is a Vero cell line stably expressing viral envelope proteins, while it undergoes single-cycle replication in naïve cells and completely lacks neurovirulence in suckling mice after intracranial inoculation. A single-dose vaccination of mice with scMP-12 confers protective immunity. Thus, scMP-12 represents a new, promising RVF vaccine candidate. Here we describe protocols for scMP-12 generation by using a reverse genetics system, establishment of Vero-G cells, and titration of scMP-12 in Vero-G cells.

AB - Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) is an arbovirus that causes severe disease in humans and livestock in sub-Saharan African countries. The virus carries a tripartite, single-stranded, and negative–sense RNA genome, designated as L, M, and S RNAs. RVFV spread can be prevented by the effective vaccination of animals and humans. Although the MP-12 strain of RVFV is a live attenuated vaccine candidate, MP-12 showed neuroinvasiveness and neurovirulence in young mice and immunodeficiency mice. Hence, there is a concern for the use of MP-12 to certain individuals, especially those that are immunocompromised. To improve MP-12 safety, we have generated a single-cycle, replicable MP-12 (scMP-12), which carries L RNA, S RNA encoding green fluorescent protein in place of a viral nonstructural protein NSs, and an M RNA encoding a mutant envelope protein lacking an endoplasmic reticulum retrieval signal and defective for membrane fusion function. The scMP-12 undergoes efficient amplification in the Vero-G cell line, which is a Vero cell line stably expressing viral envelope proteins, while it undergoes single-cycle replication in naïve cells and completely lacks neurovirulence in suckling mice after intracranial inoculation. A single-dose vaccination of mice with scMP-12 confers protective immunity. Thus, scMP-12 represents a new, promising RVF vaccine candidate. Here we describe protocols for scMP-12 generation by using a reverse genetics system, establishment of Vero-G cells, and titration of scMP-12 in Vero-G cells.

KW - Reverse genetics

KW - Rift Valley fever virus

KW - Single-cycle replicable virus

KW - Stable cell establishment

KW - Transfection

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84963818979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963818979&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3387-7_9

DO - 10.1007/978-1-4939-3387-7_9

M3 - Chapter

VL - 1403

T3 - Methods in Molecular Biology

SP - 187

EP - 206

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -